spacer
home > ebr > winter 2001 > the business model - bridging the gap between technology and economic value
PUBLICATIONS
European Biopharmaceutical Review

The Business Model - Bridging the Gap Between Technology and Economic Value

The goal of the biotech industry is to create actual treatments for unmet medical needs. Biotechnology start-ups must take technology to market through a venture shaped by a specific business model, whether explicitly considered or implicitly embodied in the act of innovation. The inherent value of a technology remains latent until it is commercialised in some way. Obviously, the extent to which its value is realised depends upon the manner in which that takes place. Thus, technology managers must expand their perspectives in order to find the right business model, or 'the architecture of revenue' in order to capture value.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Pieter van der Meer, Investment Director and Partner with the
Biotechnology Team at Gilde Investment Management in the Netherlands Pieter van der Meer is an Investment Director and Partner with the biotechnology team of the venture capital organisation, Gilde Investment Management in the Netherlands. Pieter studied at Leiden University, graduating in Bio-organic Synthesis. He worked as a Management Consultant with KPMG Management Consulting before joining Gilde in 1998. The biotechnology fund has a keen interest in applied genomics technologies such as proteomics, systems biology, structural bioinformatics and so on. Pieter also serves on the board ofseveral European early stage technology companies.

spacer
Pieter van der Meer
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

PHASTAR Names Chris Schoonmaker as Chief Operations Officer


More info >>

White Papers

Clinical Trials in Emerging Markets: Goldmines or Landmines?

Pharm-Olam, LLC

Over the past decade, biopharmaceutical companies have increasingly turned to emerging markets as a way to reduce clinical trial costs and timelines. Areas such as Eastern Europe, India, and Latin America—with their ready population of treatment naïve patients—can be an answer to the intense competition for patients seen in developed markets. Many of the countries within these regions may now be considered as “emerged” countries but yet, conducting trials in these regions does require some special attention and expertise. Before deciding to conduct studies in these areas, companies should have a full appreciation for the ethical, medical, regulatory, legal, and operational hurdles that must be surmounted for success. Here we highlight a number of those issues and offer our recommendations for how sponsor companies can deal with them effectively.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement